4'-Fluorouridine (4'-FlU, EIDD-2749) is a a broad-spectrum orally efficacious ribonucleoside analog that inhibits RSV, SARS-CoV-2 and related RNA viruse LASV, targets RSV and SARS-CoV-2 RdRP causes sequence-modulated transcriptional stalling.
4'-Fluorouridine (4'-FlU, EIDD-2749) shows potent dose-dependent activity against recombinant RSV A2-line19F (recRSV A2-L19F) and clinical RSV isolates with EC50 of 0.61-1.2 uM.
4'-Fluorouridine (4'-FlU, EIDD-2749) inhibits RSV and paramyxovirus RdRP complex activity in cell-based minireplicon systems.
4'-Fluorouridine (4'-FlU, EIDD-2749) is efficiently anabolized in HAE cells and is efficacious in human airway epithelium organoids.
4'-Fluorouridine (4'-FlU, EIDD-2749) is orally efficacious in a therapeutic dosing regimen in a small-animal model of RSV infection.
4'-Fluorouridine (4'-FlU, EIDD-2749) is effective against SARS-CoV-2 in HAE and the ferret model.
4'-Fluorouridine (4'-FlU, EIDD-2749) also potently inhibits pathogenic arenaviruses Old World Lassa virus (LASV) and New World Junín virus (JUNV), in pig models of lethal disease.